26.44
0.56%
0.04
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St
Celldex Therapeutics (NASDAQ:CLDX) Given Buy Rating at HC Wainwright - MarketBeat
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times
Celldex Launches Phase 1 Trial of Novel Dual-Action Inflammatory Disease Treatment | CLDX Stock News - StockTitan
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada
Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com
Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com
Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat
Celldex Therapeutics CEO Anthony Marucci buys $308,430 in stock By Investing.com - Investing.com UK
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan
Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat
What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com
FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Celldex: Q3 Earnings Snapshot - San Antonio Express-News
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Evommune raises $115M to accelerate immune drug tests - Yahoo Finance
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat
Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR
Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK
Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance
Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance
Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - ForexTV.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):